BL
Therapeutic Areas
Celcuity Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Gedatolisib + Palbociclib + Fulvestrant | HR+/HER2- Advanced Breast Cancer (PIK3CA Wild-Type) | Phase 3 |
| Gedatolisib + Palbociclib + Letrozole/Fulvestrant | HR+/HER2- Advanced Breast Cancer (PIK3CA Mutant) | Phase 3 |
| Gedatolisib + Darolutamide | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 1b/3 |
Leadership Team at Celcuity
BS
Brian Sullivan
Chief Executive Officer and Co-founder
LL
Lance Laing, PhD
Chief Science Officer and Co-founder
VH
Vicky Hahne
Chief Financial Officer
IG
Igor Gorbatchevsky, MD
Chief Medical Officer
EM
Eldon Mayer
Chief Commercial Officer
BE
Brent Eilefson, JD
General Counsel
NZ
Nadene Zack
Vice President, Clinical Operations
SM
Sunni Miller
Vice President, Regulatory Affairs
DB
David Bridge
Vice President, Quality Assurance and Process Development
FK
Fred Kerwood
Vice President, Program Management